methoxamine
Trade name: vasoxyl
Approved
Mar 28, 1949
Methoxamine is an alpha-adrenergic agonist that induces prolonged peripheral vasoconstriction, and can also stimulate the release of arginine vasopressin in humans. In clinical trials, methoxamine was found to improve fecal incontinence. It had been marketed by Glaxo-Smith-Kline under the brand name Vasoxyl but has been discontinued. Methoxamine was also found to stimulate the induction of hiPSC-derived hepatoblasts to ALBUMIN+ cells. — NCATS
Clinical trial activity
8 trials · 5 clinical orgs · 2 marketing orgs
Earliest trial started Apr 1, 2007 (NCT00893607)
Timeline
1940s
- Mar 28, 1949
Earliest FDA Approval
- Mar 28, 1949
GlaxoSmithKline — Marketing Organization
- Mar 28, 1949
GlaxoSmithKline — NDA Secondary Org
- Jul 9, 1949
Burroughs Wellcome — First NDA Organization
- Jul 9, 1949
Burroughs Wellcome — NDA Organization
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Adrenergic receptor alpha-1AGONIST
Adrenergic receptor alpha-1 agonist
Approval history
- approvedMar 28, 1949
Chemistry & pharmacology
SMILES
COc1ccc(OC)c(C(O)C(C)N)c1- Mol. weight
- 211.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL524 ↗
- WikipediaMethoxamine ↗
- NCATSHUQ1KC1YLI ↗
- ChEMBLCHEMBL1201103 ↗
Also known as
- 1r, 2s-methoxamine hydrochloride
- méthoxamédrine
- méthoxamédrine
- methoxamin
- methoxamin
- methoxamin
- methoxamine
- methoxamine
- methoxamine
- methoxamine
- methoxamine
- methoxamine
- methoxamine
- methoxamine
- methoxamine
- methoxamine
- méthoxamine
- méthoxamine
- methoxamine hcl
- methoxamine hcl
- methoxamine hcl
- methoxamine hydrochloride
- methoxamine hydrochloride
- methoxamine hydrochloride
- methoxamine hydrochloride
- methoxaminum
- methoxaminum
- metossamina
- metossamina
- metoxamina
- metoxamina
- nrl001
- pseudomethoxamine
- pseudomethoxamine
- vasoxine
- vasoxine
- vasoxyl
- vasoxyl
- vasoxyl
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01656720 | Phase 2 | Feb 1, 2012 | Norgine, University of Rennes |
| NCT01175941 | Phase 1 | Aug 1, 2010 | Norgine, University of Nottingham |
| NCT01099683 | Phase 1 | Apr 1, 2010 | Bio-Kinetic Clinical Applications, Norgine |
| NCT01099670 | Phase 1 | Mar 1, 2010 | Bio-Kinetic Clinical Applications, Norgine |
| NCT00850590 | Phase 1 | Feb 1, 2009 | Biokinetic Europe Ltd, Norgine |
| NCT00857467 | Phase 1 | Feb 1, 2009 | Norgine, University of Nottingham |
| NCT00893607 | Phase 1 | Apr 1, 2007 | Norgine |
| NCT01406925 | Phase 1 | Apr 1, 2007 | Norgine |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Norgine | For profit | 8 | 8 | 2 | 2007 |
| Bio-Kinetic Clinical Applications | For profit | 2 | 0 | 1 | 2010 |
| University of Nottingham | Academic/Hospital | 2 | 0 | 1 | 2009 |
| Biokinetic Europe Ltd | For profit | 1 | 0 | 1 | 2009 |
| University of Rennes | Academic/Hospital | 1 | 0 | 1 | 2012 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Burroughs Wellcome | For profit | NDA | Jul 9, 1949 |
| GlaxoSmithKline | For profit | MKTG | Mar 28, 1949 |
| GlaxoSmithKline | For profit | NDA2 | Mar 28, 1949 |